Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Viking Therapeutics (VKTX) over the last 11 years, with Q3 2025 value amounting to $5.2 million.

  • Viking Therapeutics' Gains from Investment Securities rose 464525.87% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 8774.62%. This contributed to the annual value of $4.7 million for FY2024, which is 979.72% down from last year.
  • Per Viking Therapeutics' latest filing, its Gains from Investment Securities stood at $5.2 million for Q3 2025, which was up 464525.87% from $5.2 million recorded in Q2 2025.
  • Viking Therapeutics' Gains from Investment Securities' 5-year high stood at $42.1 million during Q1 2024, with a 5-year trough of $109000.0 in Q3 2024.
  • For the 5-year period, Viking Therapeutics' Gains from Investment Securities averaged around $7.1 million, with its median value being $5.1 million (2022).
  • Data for Viking Therapeutics' Gains from Investment Securities shows a peak YoY increase of 464525.87% (in 2025) and a maximum YoY decrease of 8769.3% (in 2025) over the last 5 years.
  • Over the past 5 years, Viking Therapeutics' Gains from Investment Securities (Quarter) stood at $3.9 million in 2021, then skyrocketed by 30.03% to $5.1 million in 2022, then crashed by 66.44% to $1.7 million in 2023, then plummeted by 93.64% to $109000.0 in 2024, then surged by 4645.26% to $5.2 million in 2025.
  • Its Gains from Investment Securities stands at $5.2 million for Q3 2025, versus $5.2 million for Q2 2025 and $5.2 million for Q1 2025.